BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway
Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To improve the efficacy of ASNase treatment, we used a CRISPR/Cas9-based screen to identify actionable signaling intermediat...
Gespeichert in:
| Veröffentlicht in: | Blood 2021-12, Vol.138 (23), p.2383-2395 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2395 |
|---|---|
| container_issue | 23 |
| container_start_page | 2383 |
| container_title | Blood |
| container_volume | 138 |
| creator | Butler, Miriam van Ingen Schenau, Dorette S. Yu, Jiangyan Jenni, Silvia Dobay, Maria P. Hagelaar, Rico Vervoort, Britt M.T. Tee, Trisha M. Hoff, Fieke W. Meijerink, Jules P. Kornblau, Steven M. Bornhauser, Beat Bourquin, Jean-Pierre Kuiper, Roland P. van der Meer, Laurens T. van Leeuwen, Frank N. |
| description | Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To improve the efficacy of ASNase treatment, we used a CRISPR/Cas9-based screen to identify actionable signaling intermediates that improve the response to ASNase. Both genetic inactivation of Bruton's tyrosine kinase (BTK) and pharmacological inhibition by the BTK inhibitor ibrutinib strongly synergize with ASNase by inhibiting the amino acid response pathway, a mechanism involving c-Myc–mediated suppression of GCN2 activity. This synthetic lethal interaction was observed in 90% of patient-derived xenografts, regardless of the genomic subtype. Moreover, ibrutinib substantially improved ASNase treatment response in a murine PDX model. Hence, ibrutinib may be used to enhance the clinical efficacy of ASNase in ALL. This trial was registered at www.clinicaltrials.gov as # NCT02884453.
•CRISPR/Cas9 kinome screen identifies genes involved in ASNase sensitivity.•Ibrutinib synergizes with ASNase by inhibiting the amino acid response pathway via c-Myc– mediated regulation of GCN2.
[Display omitted] |
| doi_str_mv | 10.1182/blood.2021011787 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8832462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497121013720</els_id><sourcerecordid>2553522728</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-2f89ba3191ffae0a2e02f1dd67302739402ae01d2e7a265d30ba05c5ba2c789c3</originalsourceid><addsrcrecordid>eNp1kcFv1TAMxiMEYm-DOyeUI5cOx21f8zggwcQAMYnLOEdu6r4G2qQ06dDjryfwxoADJ1v2z58tf0I8UXCulMbn7RhCd46ACpRqdHNPbFSNugBAuC82ALAtql2jTsRpjJ8BVFVi_VCclBVqwFpvxPr6-oN0fnCtSy54GdnHnH3nKMmuieV4mOYhtCPF5Kwcef3CkyOZgqQ400J75ymybA8yrvO8cIzO72UaWNLkfKas62Quz8FnbKY0fKPDI_GgpzHy49t4Jj5dvrm-eFdcfXz7_uLVVWGrqkkF9nrXUql2qu-JgZABe9V126YEbMpdBZjLqkNuCLd1V0JLUNu6JbSN3tnyTLw86s5rO3Fn2aeFRjMvbqLlYAI582_Hu8Hsw43RusRqi1ng2a3AEr6uHJOZXLQ8juQ5rNFgXZc1YoM6o3BE7RJiXLi_W6PA_HTL_HLL_HErjzz9-7y7gd_2ZODFEeD8pBvHi4nWsbfcuYVtMl1w_1f_AYNeqL0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553522728</pqid></control><display><type>article</type><title>BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Butler, Miriam ; van Ingen Schenau, Dorette S. ; Yu, Jiangyan ; Jenni, Silvia ; Dobay, Maria P. ; Hagelaar, Rico ; Vervoort, Britt M.T. ; Tee, Trisha M. ; Hoff, Fieke W. ; Meijerink, Jules P. ; Kornblau, Steven M. ; Bornhauser, Beat ; Bourquin, Jean-Pierre ; Kuiper, Roland P. ; van der Meer, Laurens T. ; van Leeuwen, Frank N.</creator><creatorcontrib>Butler, Miriam ; van Ingen Schenau, Dorette S. ; Yu, Jiangyan ; Jenni, Silvia ; Dobay, Maria P. ; Hagelaar, Rico ; Vervoort, Britt M.T. ; Tee, Trisha M. ; Hoff, Fieke W. ; Meijerink, Jules P. ; Kornblau, Steven M. ; Bornhauser, Beat ; Bourquin, Jean-Pierre ; Kuiper, Roland P. ; van der Meer, Laurens T. ; van Leeuwen, Frank N.</creatorcontrib><description>Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To improve the efficacy of ASNase treatment, we used a CRISPR/Cas9-based screen to identify actionable signaling intermediates that improve the response to ASNase. Both genetic inactivation of Bruton's tyrosine kinase (BTK) and pharmacological inhibition by the BTK inhibitor ibrutinib strongly synergize with ASNase by inhibiting the amino acid response pathway, a mechanism involving c-Myc–mediated suppression of GCN2 activity. This synthetic lethal interaction was observed in 90% of patient-derived xenografts, regardless of the genomic subtype. Moreover, ibrutinib substantially improved ASNase treatment response in a murine PDX model. Hence, ibrutinib may be used to enhance the clinical efficacy of ASNase in ALL. This trial was registered at www.clinicaltrials.gov as # NCT02884453.
•CRISPR/Cas9 kinome screen identifies genes involved in ASNase sensitivity.•Ibrutinib synergizes with ASNase by inhibiting the amino acid response pathway via c-Myc– mediated regulation of GCN2.
[Display omitted]</description><identifier>ISSN: 0006-4971</identifier><identifier>ISSN: 1528-0020</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2021011787</identifier><identifier>PMID: 34280258</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenine - analogs & derivatives ; Adenine - pharmacology ; Adenine - therapeutic use ; Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase - metabolism ; Amino Acids - metabolism ; Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Apoptosis - drug effects ; Asparaginase - pharmacology ; Asparaginase - therapeutic use ; Cell Line, Tumor ; Humans ; Lymphoid Neoplasia ; Mice ; Piperidines - pharmacology ; Piperidines - therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism ; Signal Transduction - drug effects</subject><ispartof>Blood, 2021-12, Vol.138 (23), p.2383-2395</ispartof><rights>2021 American Society of Hematology</rights><rights>2021 by The American Society of Hematology.</rights><rights>2021 by The American Society of Hematology 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-2f89ba3191ffae0a2e02f1dd67302739402ae01d2e7a265d30ba05c5ba2c789c3</citedby><cites>FETCH-LOGICAL-c447t-2f89ba3191ffae0a2e02f1dd67302739402ae01d2e7a265d30ba05c5ba2c789c3</cites><orcidid>0000-0002-6860-798X ; 0000-0002-7128-1255 ; 0000-0003-1622-6293</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34280258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Butler, Miriam</creatorcontrib><creatorcontrib>van Ingen Schenau, Dorette S.</creatorcontrib><creatorcontrib>Yu, Jiangyan</creatorcontrib><creatorcontrib>Jenni, Silvia</creatorcontrib><creatorcontrib>Dobay, Maria P.</creatorcontrib><creatorcontrib>Hagelaar, Rico</creatorcontrib><creatorcontrib>Vervoort, Britt M.T.</creatorcontrib><creatorcontrib>Tee, Trisha M.</creatorcontrib><creatorcontrib>Hoff, Fieke W.</creatorcontrib><creatorcontrib>Meijerink, Jules P.</creatorcontrib><creatorcontrib>Kornblau, Steven M.</creatorcontrib><creatorcontrib>Bornhauser, Beat</creatorcontrib><creatorcontrib>Bourquin, Jean-Pierre</creatorcontrib><creatorcontrib>Kuiper, Roland P.</creatorcontrib><creatorcontrib>van der Meer, Laurens T.</creatorcontrib><creatorcontrib>van Leeuwen, Frank N.</creatorcontrib><title>BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway</title><title>Blood</title><addtitle>Blood</addtitle><description>Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To improve the efficacy of ASNase treatment, we used a CRISPR/Cas9-based screen to identify actionable signaling intermediates that improve the response to ASNase. Both genetic inactivation of Bruton's tyrosine kinase (BTK) and pharmacological inhibition by the BTK inhibitor ibrutinib strongly synergize with ASNase by inhibiting the amino acid response pathway, a mechanism involving c-Myc–mediated suppression of GCN2 activity. This synthetic lethal interaction was observed in 90% of patient-derived xenografts, regardless of the genomic subtype. Moreover, ibrutinib substantially improved ASNase treatment response in a murine PDX model. Hence, ibrutinib may be used to enhance the clinical efficacy of ASNase in ALL. This trial was registered at www.clinicaltrials.gov as # NCT02884453.
•CRISPR/Cas9 kinome screen identifies genes involved in ASNase sensitivity.•Ibrutinib synergizes with ASNase by inhibiting the amino acid response pathway via c-Myc– mediated regulation of GCN2.
[Display omitted]</description><subject>Adenine - analogs & derivatives</subject><subject>Adenine - pharmacology</subject><subject>Adenine - therapeutic use</subject><subject>Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors</subject><subject>Agammaglobulinaemia Tyrosine Kinase - metabolism</subject><subject>Amino Acids - metabolism</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Asparaginase - pharmacology</subject><subject>Asparaginase - therapeutic use</subject><subject>Cell Line, Tumor</subject><subject>Humans</subject><subject>Lymphoid Neoplasia</subject><subject>Mice</subject><subject>Piperidines - pharmacology</subject><subject>Piperidines - therapeutic use</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</subject><subject>Signal Transduction - drug effects</subject><issn>0006-4971</issn><issn>1528-0020</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFv1TAMxiMEYm-DOyeUI5cOx21f8zggwcQAMYnLOEdu6r4G2qQ06dDjryfwxoADJ1v2z58tf0I8UXCulMbn7RhCd46ACpRqdHNPbFSNugBAuC82ALAtql2jTsRpjJ8BVFVi_VCclBVqwFpvxPr6-oN0fnCtSy54GdnHnH3nKMmuieV4mOYhtCPF5Kwcef3CkyOZgqQ400J75ymybA8yrvO8cIzO72UaWNLkfKas62Quz8FnbKY0fKPDI_GgpzHy49t4Jj5dvrm-eFdcfXz7_uLVVWGrqkkF9nrXUql2qu-JgZABe9V126YEbMpdBZjLqkNuCLd1V0JLUNu6JbSN3tnyTLw86s5rO3Fn2aeFRjMvbqLlYAI582_Hu8Hsw43RusRqi1ng2a3AEr6uHJOZXLQ8juQ5rNFgXZc1YoM6o3BE7RJiXLi_W6PA_HTL_HLL_HErjzz9-7y7gd_2ZODFEeD8pBvHi4nWsbfcuYVtMl1w_1f_AYNeqL0</recordid><startdate>20211209</startdate><enddate>20211209</enddate><creator>Butler, Miriam</creator><creator>van Ingen Schenau, Dorette S.</creator><creator>Yu, Jiangyan</creator><creator>Jenni, Silvia</creator><creator>Dobay, Maria P.</creator><creator>Hagelaar, Rico</creator><creator>Vervoort, Britt M.T.</creator><creator>Tee, Trisha M.</creator><creator>Hoff, Fieke W.</creator><creator>Meijerink, Jules P.</creator><creator>Kornblau, Steven M.</creator><creator>Bornhauser, Beat</creator><creator>Bourquin, Jean-Pierre</creator><creator>Kuiper, Roland P.</creator><creator>van der Meer, Laurens T.</creator><creator>van Leeuwen, Frank N.</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6860-798X</orcidid><orcidid>https://orcid.org/0000-0002-7128-1255</orcidid><orcidid>https://orcid.org/0000-0003-1622-6293</orcidid></search><sort><creationdate>20211209</creationdate><title>BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway</title><author>Butler, Miriam ; van Ingen Schenau, Dorette S. ; Yu, Jiangyan ; Jenni, Silvia ; Dobay, Maria P. ; Hagelaar, Rico ; Vervoort, Britt M.T. ; Tee, Trisha M. ; Hoff, Fieke W. ; Meijerink, Jules P. ; Kornblau, Steven M. ; Bornhauser, Beat ; Bourquin, Jean-Pierre ; Kuiper, Roland P. ; van der Meer, Laurens T. ; van Leeuwen, Frank N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-2f89ba3191ffae0a2e02f1dd67302739402ae01d2e7a265d30ba05c5ba2c789c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Adenine - pharmacology</topic><topic>Adenine - therapeutic use</topic><topic>Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors</topic><topic>Agammaglobulinaemia Tyrosine Kinase - metabolism</topic><topic>Amino Acids - metabolism</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Asparaginase - pharmacology</topic><topic>Asparaginase - therapeutic use</topic><topic>Cell Line, Tumor</topic><topic>Humans</topic><topic>Lymphoid Neoplasia</topic><topic>Mice</topic><topic>Piperidines - pharmacology</topic><topic>Piperidines - therapeutic use</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism</topic><topic>Signal Transduction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Butler, Miriam</creatorcontrib><creatorcontrib>van Ingen Schenau, Dorette S.</creatorcontrib><creatorcontrib>Yu, Jiangyan</creatorcontrib><creatorcontrib>Jenni, Silvia</creatorcontrib><creatorcontrib>Dobay, Maria P.</creatorcontrib><creatorcontrib>Hagelaar, Rico</creatorcontrib><creatorcontrib>Vervoort, Britt M.T.</creatorcontrib><creatorcontrib>Tee, Trisha M.</creatorcontrib><creatorcontrib>Hoff, Fieke W.</creatorcontrib><creatorcontrib>Meijerink, Jules P.</creatorcontrib><creatorcontrib>Kornblau, Steven M.</creatorcontrib><creatorcontrib>Bornhauser, Beat</creatorcontrib><creatorcontrib>Bourquin, Jean-Pierre</creatorcontrib><creatorcontrib>Kuiper, Roland P.</creatorcontrib><creatorcontrib>van der Meer, Laurens T.</creatorcontrib><creatorcontrib>van Leeuwen, Frank N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Butler, Miriam</au><au>van Ingen Schenau, Dorette S.</au><au>Yu, Jiangyan</au><au>Jenni, Silvia</au><au>Dobay, Maria P.</au><au>Hagelaar, Rico</au><au>Vervoort, Britt M.T.</au><au>Tee, Trisha M.</au><au>Hoff, Fieke W.</au><au>Meijerink, Jules P.</au><au>Kornblau, Steven M.</au><au>Bornhauser, Beat</au><au>Bourquin, Jean-Pierre</au><au>Kuiper, Roland P.</au><au>van der Meer, Laurens T.</au><au>van Leeuwen, Frank N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2021-12-09</date><risdate>2021</risdate><volume>138</volume><issue>23</issue><spage>2383</spage><epage>2395</epage><pages>2383-2395</pages><issn>0006-4971</issn><issn>1528-0020</issn><eissn>1528-0020</eissn><abstract>Asparaginase (ASNase) therapy has been a mainstay of acute lymphoblastic leukemia (ALL) protocols for decades and shows promise in the treatment of a variety of other cancers. To improve the efficacy of ASNase treatment, we used a CRISPR/Cas9-based screen to identify actionable signaling intermediates that improve the response to ASNase. Both genetic inactivation of Bruton's tyrosine kinase (BTK) and pharmacological inhibition by the BTK inhibitor ibrutinib strongly synergize with ASNase by inhibiting the amino acid response pathway, a mechanism involving c-Myc–mediated suppression of GCN2 activity. This synthetic lethal interaction was observed in 90% of patient-derived xenografts, regardless of the genomic subtype. Moreover, ibrutinib substantially improved ASNase treatment response in a murine PDX model. Hence, ibrutinib may be used to enhance the clinical efficacy of ASNase in ALL. This trial was registered at www.clinicaltrials.gov as # NCT02884453.
•CRISPR/Cas9 kinome screen identifies genes involved in ASNase sensitivity.•Ibrutinib synergizes with ASNase by inhibiting the amino acid response pathway via c-Myc– mediated regulation of GCN2.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34280258</pmid><doi>10.1182/blood.2021011787</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-6860-798X</orcidid><orcidid>https://orcid.org/0000-0002-7128-1255</orcidid><orcidid>https://orcid.org/0000-0003-1622-6293</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2021-12, Vol.138 (23), p.2383-2395 |
| issn | 0006-4971 1528-0020 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8832462 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adenine - analogs & derivatives Adenine - pharmacology Adenine - therapeutic use Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Agammaglobulinaemia Tyrosine Kinase - metabolism Amino Acids - metabolism Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis - drug effects Asparaginase - pharmacology Asparaginase - therapeutic use Cell Line, Tumor Humans Lymphoid Neoplasia Mice Piperidines - pharmacology Piperidines - therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Signal Transduction - drug effects |
| title | BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T03%3A49%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BTK%20inhibition%20sensitizes%20acute%20lymphoblastic%20leukemia%20to%20asparaginase%20by%20suppressing%20the%20amino%20acid%20response%20pathway&rft.jtitle=Blood&rft.au=Butler,%20Miriam&rft.date=2021-12-09&rft.volume=138&rft.issue=23&rft.spage=2383&rft.epage=2395&rft.pages=2383-2395&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2021011787&rft_dat=%3Cproquest_pubme%3E2553522728%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2553522728&rft_id=info:pmid/34280258&rft_els_id=S0006497121013720&rfr_iscdi=true |